TABLE 2.
Plasma marker measures, overall and by APOE ε4 status, in American Indian participants of the Strong Heart Study (2017–2019).
|
Overall N = 401 |
No APOE ε4 allele n = 314 |
APOE ε4 carrier n = 83 |
Percent difference: APOE ε4 versus not | p‐Value | FDR Q‐value | |
|---|---|---|---|---|---|---|
| pTau181 pg/mL | 5.0 (3.5, 7.4) | 4.9 (3.4, 7.2) | 5.5 (3.9, 8.3) | + 12% | 0.067 | 0.182 |
| Aβ40 pg/mL | 128 (116, 175) | 128 (116, 175) | 127 (113, 177) | ‐0.8% | 0.780 | 0.780 |
| Aβ42 pg/mL | 8.2 (6.7, 9.7) | 8.3 (6.8, 9.8) | 7.6 (6.2, 9.4) | ‐8.4% | 0.140 | 0.210 |
| Aβ42/40 ratio | 0.06 (0.05, 0.07) | 0.06 (0.05, 0.07) | 0.05 (0.04, 0.06) | ‐ 16.7% | 0.001 | 0.006 |
| GFAP pg/mL | 150 (114, 218) | 149 (112, 215) | 173 (121, 240) | + 16.1% | 0.091 | 0.182 |
| NfL pg/mL | 31.6 (23.0, 48.9) | 31.5 (22.9, 48.6) | 31.8 (23.4, 49.6) | + 3.2% | 0.470 | 0.564 |
Note: Values provided as med (IQR) unless otherwise indicated. p‐Values based on Wilcoxon rank‐sum test; FDR (false discovery rate). Q‐value based on Benjamini–Hochberg method and assessed for significance at Q < 0.1.
Abbreviations: APOE, apoprotein E; Aβ, amyloid‐beta; GFAP, glial fibrillary protein; NfL, neurofilament light chain; pTau, phosphorylated tau.